Biopharma Funds Are Still Embracing VC

The number of deals is down from last year, but most firms have still been fairly active in the private markets.

Stephen Taub December 21, 2022

Carsten Snejbjerg/Bloomberg

Biopharma-focused hedge funds have cut back sharply on their private venture capital investments in 2022, but not to the extent of the tech-focused firms. Yes, they all participated in fewer private fundraisings

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Market Intelligence

Data & Analysis

Guest Contributors

II Networks

Insights

Research

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.12.01 build:2025-12-11 Login